Wilex Starts Patient Enrollment in Rencarex® (WX-G250) Pivotal Phase III Trial in Renal Cell Carcinoma
15-Jun-2004 -
Munich. Wilex AG, Munich, a privately held
biopharmaceutical company dedicated to the development of novel cancer
therapies, announced that the pivotal Phase III study with Rencarex®
in renal cell carcinoma (RCC) has started enrolling patients.
The multi-center, global, randomized study has been ...
food
phase III studies
statistics
+2